Hemophilia

Hemophilia


​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Data Elements


DEMOGRAPHICS

  • Diagnosis
  • Age
  • Gender
  • Race / Ethnicity
  • BMI
  • Height / Weight

PT CHARACTERISTICS

  • Hemophilia Severity
  • IV Access Method
  • Target Joints
  • Prophylaxis vs. Breakthrough Bleeding Products
  • Inhibitor Use
  • Last Bleed Date
  • Number of Bleeds

PRIOR HISTORY

  • First Diagnosis of Hemophilia Date
  • Prior Regimen
  • Prior Treatment Status (new to therapy or refill)
  • Duration of Therapy
  • Reason for Switch

PT ADHERENCE

  • Current Therapy
  • Duration
  • Dose
  • Prophylaxis Product Use
  • Bleeding Product Use
  • % Doses Taken
  • % Doses Missed

PROVIDERS

  • Type (Physician, NP, PA)
  • Specialty
  • Academic vs Community
  • Specialty Pharmacy vs. Hemophilia Treatment Center

PAYERS

  • Type (Commercial, Medicare, Medicaid, Dual Eligible)
  • Payer Name
  • Self-Pay and Patient Assistance
  • Eligibility
  • Correct PA form
  • Denial Reason

PA TIMELINE

  • Copay Amount
  • PA Submitted Date
  • Approval / Denial Date
  • Appeals Submitted

DISPENSING INFO

  • Current Treatment Regimen Rx
  • Intended Regimen
  • Actual Regimen
  • Duration
  • Dispensed Regimen
  • Duration / Refills
  • Gaps in Therapy

Patient Tear Sheet


Real Time Aggregated Data is organized and visualized at a patient level for immediate and longitudinal insight.
Click on image below for a 3 page PDF of a Patient Tear Sheet.

Publications


2021


A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A

Shawn X. Sun, Andrew Frick

10.18553/jmcp.2021.27.4-a.s1

Poster Presented at: Academy of Managed Care Pharmacy (AMCP)

Conference dates: April 12, 2021 - April 16, 2021


A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice

Shawn X. Sun, Andrew Frick

DOI: 10.1111/hae.14236: ABS039

Poster Presented at: European Association for Haemophilia and Allied Disorders

Conference dates: February 03, 2021 - February 05, 2021




2020


Real-World Outcomes Before and After Switching From Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in The United States

Shawn X. Sun, Scott Milligan

Res Pract Thromb Haemost. 2020; 4 (Suppl 1)

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 12, 2020 - July 14, 2020


A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States

Louis Aledort, MD; Scott Milligan, PhD; Maureen Watt, MSc; and Jason Booth, MPH

DOI: 10.18553/jmcp.2020.26.4.492

Manuscript Published in: Journal of Managed Care & Specialty Pharmacy

Date of Publication: April 01, 2020




2019


Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data

Maureen Watt and Scott Milligan

DOI: 10.1182/blood-2019-124101

Poster Presented at: The American Society of Hematology (ASH)

Conference dates: December 07, 2019 - December 10, 2019


A Retrospective, Observational Study Using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States

Maureen Watt and Scott Milligan

DOI: 10.1002/rth2.12229

Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)

Conference dates: July 06, 2019 - July 10, 2019




2018


A Retrospective, Observational Study of BAX 855 in Clinical Practice in the United States

J. Booth, M. Watt, S. Milligan, and L. Aledort

DOI: 10.18553/jmcp.2018.24.4-a.s1

Poster Presented at: Academy of Managed Care Pharmacy (AMCP)

Conference dates: April 23, 2018 - April 26, 2018